Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2019, Article ID 7593560, 8 pages
https://doi.org/10.1155/2019/7593560
Review Article

Prognostic Significance of the Lymphocyte-to-Monocyte Ratio in Bladder Cancer Undergoing Radical Cystectomy: A Meta-Analysis of 5638 Individuals

Department of Breast Surgery, Thyroid Surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, No. 141, Tianjin Road, Huangshi, Hubei, China

Correspondence should be addressed to Qin Liu; moc.621@qlyyxzsh

Received 15 November 2018; Revised 23 December 2018; Accepted 27 December 2018; Published 4 April 2019

Academic Editor: Massimiliano M. Corsi Romanelli

Copyright © 2019 Jian-ying Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. A growing number of studies have explored the association between the pretreatment lymphocyte-to-monocyte ratio (LMR) and survival outcomes in various cancers. However, its prognostic significance on bladder cancer remains inconsistent. The aim of this meta-analysis was to evaluate the prognostic value of pretreatment LMR in bladder cancer. Methods. The MEDLINE, EMBASE, Cochrane Library, and CNKI databases were comprehensively searched for relevant studies. A meta-analysis of overall survival (OS), recurrence-free survival (RFS), or cancer-specific survival (CSS) clinicopathological features was conducted. Results. Nine studies containing 5,638 cancer patients were analyzed in this meta-analysis. Patients with high LMR tended to have favourable OS (HR: 0.63, 95% CI: 0.50-0.80, ), RFS (HR: 0.59, 95% CI: 0.38-0.91, ), and CSS (HR: 0.76, 95% CI: 0.70-0.83, ). Moreover, low LMR was highly correlated with age (≥60), differentiation (low), T stage (III-IV), lymph node metastasis (yes), and concomitant Cis (yes). Conclusion. Pretreatment LMR might be a useful predictor of survival outcomes in patients with bladder cancer.